Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma

Tao, Yuquan; Shan, Liang; Xu, Xin; Jiang, Hongyuan; Chen, Rui; Qian, Zijun; Yang, Zongguo; Liang, Bin; Zheng, Haiyin; Cai, Feng; Yu, Yongchun; Ma, Lifang

doi:10.7150/jca.25909



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(21):3962-3970. doi:10.7150/jca.25909 This issue Cite

Research Paper

Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma

Yuquan Tao¹, Liang Shan¹, Xin Xu¹, Hongyuan Jiang¹, Rui Chen¹, Zijun Qian¹, Zongguo Yang^1,2, Bin Liang³, Haiyin Zheng³, Feng Cai³, Yongchun Yu^1,4✉, Lifang Ma^3✉

1. Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, P.R. China.
2. Shanghai Public Health Clinical Center, Fudan University, Shanghai, 201508, P.R. China.
3. Department of Clinical Laboratory Medicine, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200071, P.R. China.
4. Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, 200030, P.R. China.

Citation:

Tao Y, Shan L, Xu X, Jiang H, Chen R, Qian Z, Yang Z, Liang B, Zheng H, Cai F, Yu Y, Ma L. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. J Cancer 2018; 9(21):3962-3970. doi:10.7150/jca.25909. https://www.jcancer.org/v09p3962.htm

Other styles

Abstract

For unresectable Hepatocellular carcinoma (HCC), chemotherapy is still an important treatment strategy. Oxaliplatin (Oxa) is an effective treatment of HCC after sorafenib treatment failure. However, the intrinsic or acquired resistance of Oxa affected the chemotherapeutic sensitivity. By analyzing the data of GEO Database, we found that Oxa aberrantly increased the expression of Cysteine-rich61 (Cyr61) in HCC cell lines. Subsequently, in Bel-7404 and SMMC-7721 cells after treated with Oxa, it was verified that the expression of Cyr61 and Yes-associated protein (YAP) was increased. Moreover, we found that blockade of YAP promoted Oxa-induced cell apoptosis for the first time. Meanwhile, our previous study demonstrated that Huaier (HE) inhibited the expression of YAP. Further study found that combination treatment of Oxa and HE had a significantly synergistic anti-cancer effect and significantly inhibited the expression of YAP and apoptosis related proteins. Taken together, we have observed that overexpression of YAP significantly reduced the chemotherapeutic sensitivity of Oxa in HCC for the first time. Combination treatment of Oxa and HE solved this problem.

Keywords: YAP, chemotherapeutic sensitivity, oxaliplatin, Huaier, synergistic effect, Hepatocellular carcinoma

Citation styles

APA

Tao, Y., Shan, L., Xu, X., Jiang, H., Chen, R., Qian, Z., Yang, Z., Liang, B., Zheng, H., Cai, F., Yu, Y., Ma, L. (2018). Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. Journal of Cancer, 9(21), 3962-3970. https://doi.org/10.7150/jca.25909.

ACS

Tao, Y.; Shan, L.; Xu, X.; Jiang, H.; Chen, R.; Qian, Z.; Yang, Z.; Liang, B.; Zheng, H.; Cai, F.; Yu, Y.; Ma, L. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. J. Cancer 2018, 9 (21), 3962-3970. DOI: 10.7150/jca.25909.

NLM

CSE

Tao Y, Shan L, Xu X, Jiang H, Chen R, Qian Z, Yang Z, Liang B, Zheng H, Cai F, Yu Y, Ma L. 2018. Huaier Augmented the Chemotherapeutic Sensitivity of Oxaliplatin via Downregulation of YAP in Hepatocellular Carcinoma. J Cancer. 9(21):3962-3970.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.